Modafinil

Home » Supplements » Modafinil

Table of Contents

Cognitive enhancement

In 2003 Psychopharmacology published a 60-participant, double-blind study in which subjects who received either a 100 mg or 200 mg of modafinil displayed improved cognitive performance and reported feeling more alert when compared to a placebo group. [Source]
In 2013 Neuropharmacology published a double-blind study in which 32 subjects received 200 mg of modafinil and 32 subjects received a placebo. Compared to the placebo group, the modafinil group saw improvements in spatial working memory, planning and decision-making at the most difficult levels. [Source]
In 2013 the Public Library of Science published a double-blind, placebo-controlled study which found that a single 100 mg dose of modafinil improved cognitive performance in healthy subjects. MRI brain scans also showed increased activation of the frontal parietal control and dorsal attention networks. [Source]

In 2004 Human Psychopharmacology published a double-blind study in which 18 healthy volunteers received either a placebo or an average dose of 300 mg modafinil. Compared to those in the placebo group, subjects who received modafinil experienced improvements in fatigue, motivation, reaction time and vigilance. [Source]

In 2015 Physiology & Behavior published an animal study which found that rats performed maze tests more quickly when receiving modafinil compared to a control group. [Source]

In 2010 Drug Alcohol Dependence published a double-blind, 210-patient study which found that 200 mg per day modafinil increased the number of consecutive non-use days in individuals with cocaine addition, when compared to a placebo. [Source]

In 2010 The Annals of Pharmacotherapy published a meta-analysis of 6 studies which found that in most of studies reviewed modafinil had a positive effect of MS-related fatigue. [Source]
In 2010 Clinical Neurology and Neurosurgery published a study which found that modafinil was most beneficial to patients when MS-fatigue was accompanied by daytime sleepiness. [Source]
In 2002 the Journal of Neurology published a 3-month study of in which 47 MS patients were treated with 25-300 mg/day modafinil for 3 months. Eighty-seven percent (41 patients) self-reported clear improvement in fatigue. The authors concluded that low dose modafinil significantly improves fatigue and sleepiness and is well tolerated by MS patients. [Source]

In 2015 Psychopharmacology published an animal study which found that modafinil could be a beneficial adjunct to antiepileptic drugs. [Source]

In 2003 Movement Disorders published a double-blind, crossover study in which 21 Parkinson’s disease patients with sleepiness received either a placebo or 200 mg/day modafinil for 3 weeks. The results showed that modafinil was modestly effective for treating excessive daytime sleepiness associated with Parkinson’s disease. [Source]

In 2016 The European Respiratory Journal published a meta-analysis of 10 studies including 1466 patients which found that modafinil and armodafinil improved daytime sleepiness associated with obstructive sleep apnea. [Source]

In 2010 Cancer published a double-blind, placebo-controlled trial of 867 cancer patients undergoing chemotherapy. The results showed that 200 mg/day modafinil was effective in reducing fatigue in patients with severe fatigue but not those with mild or moderate fatigue. [Source]

In 2010 Medical Science Monitor published a meta-analysis of 9 trials involving 1,054 patients which showed that modafinil reduced excessive daytime sleepiness as well as the number of sleep attacks and naps per day when compared to a placebo. [Source]